Biotech · Private company · Morgantown, WV, US
Modulation Therapeutics, Inc.
Track this companyFree. Adds Modulation Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials11 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- 152 microCi of 225Ac-MTI-201Phase 1 · Uveal MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- 19 microCi of 225Ac-MTI-201Phase 1 · Uveal MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- 38 microCi of 225Ac-MTI-201Phase 1 · Uveal MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- 4.7 microCi 225Ac-MTI-201Phase 1 · Uveal MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- 76 microCi of 225Ac-MTI-201Phase 1 · Uveal MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- 9.5 microCi of 225Ac-MTI-201Phase 1 · Uveal MelanomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials1
- Targeted Alpha Particle Radiotherapy for Metastatic Uveal MelanomaPHASE1 · ACTIVE_NOT_RECRUITING · started Jul 21, 2022ClinicalTrials.gov NCT05496686 · fetched Nov 12, 2026
NIH awards2
- Modulation of cancer induced immune suppression via inhibition of SCD1Fiscal year 2025 · $217.7KNIH RePORTER 3R44CA272064-03S1 · fetched Nov 12, 2026
- Modulation of cancer induced immune suppression via inhibition of SCD1Fiscal year 2024 · $670.4KNIH RePORTER 5R44CA272064-03 · fetched Nov 12, 2026